235 related articles for article (PubMed ID: 30189252)
1. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets.
Bourgeois A; Omura J; Habbout K; Bonnet S; Boucherat O
Int J Biochem Cell Biol; 2018 Nov; 104():9-13. PubMed ID: 30189252
[TBL] [Abstract][Full Text] [Related]
2. Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension.
Luna RCP; de Oliveira Y; Lisboa JVC; Chaves TR; de Araújo TAM; de Sousa EE; Miranda Neto M; Pirola L; Braga VA; de Brito Alves JL
Braz J Med Biol Res; 2018 Oct; 51(12):e7437. PubMed ID: 30365723
[TBL] [Abstract][Full Text] [Related]
3. Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.
Thompson AAR; Lawrie A
Trends Mol Med; 2017 Jan; 23(1):31-45. PubMed ID: 27989641
[TBL] [Abstract][Full Text] [Related]
4. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Orriols M; Gomez-Puerto MC; Ten Dijke P
Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
[TBL] [Abstract][Full Text] [Related]
5. [New insights in the pathogenesis of pulmonary arterial hypertension].
Bordenave J; Tu L; Savale L; Huertas A; Humbert M; Guignabert C
Rev Mal Respir; 2019 Apr; 36(4):433-437. PubMed ID: 31010759
[TBL] [Abstract][Full Text] [Related]
6. [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?].
Dumas SJ; Humbert M; Cohen-Kaminsky S
Biol Aujourdhui; 2016; 210(4):171-189. PubMed ID: 28327277
[TBL] [Abstract][Full Text] [Related]
7. Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.
Ruffenach G; Chabot S; Tanguay VF; Courboulin A; Boucherat O; Potus F; Meloche J; Pflieger A; Breuils-Bonnet S; Nadeau V; Paradis R; Tremblay E; Girerd B; Hautefort A; Montani D; Fadel E; Dorfmuller P; Humbert M; Perros F; Paulin R; Provencher S; Bonnet S
Am J Respir Crit Care Med; 2016 Nov; 194(10):1273-1285. PubMed ID: 27149112
[TBL] [Abstract][Full Text] [Related]
8. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets of the Warburg effect and inflammatory cytokines in the pathogenesis of pulmonary artery hypertension.
Liu N; Parry S; Xiao Y; Zhou S; Liu Q
Clin Chim Acta; 2017 Mar; 466():98-104. PubMed ID: 28093201
[TBL] [Abstract][Full Text] [Related]
10. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.
Hu L; Zhao C; Chen Z; Hu G; Li X; Li Q
Drug Discov Today; 2022 May; 27(5):1457-1463. PubMed ID: 35104622
[TBL] [Abstract][Full Text] [Related]
11. Current drug targets and future therapy of pulmonary arterial hypertension.
Ito T; Ozawa K; Shimada K
Curr Med Chem; 2007; 14(6):719-33. PubMed ID: 17346158
[TBL] [Abstract][Full Text] [Related]
12. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
Agarwal R; Gomberg-Maitland M
Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
[TBL] [Abstract][Full Text] [Related]
13. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M
Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906
[TBL] [Abstract][Full Text] [Related]
14. Cellular and molecular pathobiology of pulmonary arterial hypertension.
Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
[TBL] [Abstract][Full Text] [Related]
15. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F
Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814
[TBL] [Abstract][Full Text] [Related]
16. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
Dumas de la Roque E; Savineau JP; Bonnet S
Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of pulmonary hypertension.
Yildiz P
Clin Chim Acta; 2009 May; 403(1-2):9-16. PubMed ID: 19361468
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
Waxman AB; Zamanian RT
Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
[TBL] [Abstract][Full Text] [Related]
19. HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Boucherat O; Chabot S; Paulin R; Trinh I; Bourgeois A; Potus F; Lampron MC; Lambert C; Breuils-Bonnet S; Nadeau V; Paradis R; Goncharova EA; Provencher S; Bonnet S
Sci Rep; 2017 Jul; 7(1):4546. PubMed ID: 28674407
[TBL] [Abstract][Full Text] [Related]
20. A review of therapeutic agents for the management of pulmonary arterial hypertension.
Hahn SS; Makaryus M; Talwar A; Narasimhan M; Zaidi G
Ther Adv Respir Dis; 2017 Jan; 11(1):46-63. PubMed ID: 27595643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
